← Patent-cliff monitor small molecule ENSACOVE ENSARTINIB HYDROCHLORIDE
Loss of exclusivity June 2037 latest FDA-listed patent expiry
Company Xcovery → See this company's full patent-cliff portfolio Drug detail Brand name ENSACOVE Active ingredient ENSARTINIB HYDROCHLORIDE Strength EQ 100MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval December 2024 Marketing status RX
Listed patents Patent Expires Type 10899744 June 2037 substance 9126947 November 2031 substance 9296724 June 2029 substance 8551995 February 2029 substance
Regulatory exclusivity Code Expires NCE December 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.